These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 30515315)

  • 1. HIV drug resistance in sub-Saharan Africa: public health questions and the potential role of real-world data and mathematical modelling.
    de Waal R; Lessells R; Hauser A; Kouyos R; Davies MA; Egger M; Wandeler G
    J Virus Erad; 2018 Nov; 4(Suppl 2):55-58. PubMed ID: 30515315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study.
    Phillips AN; Cambiano V; Nakagawa F; Revill P; Jordan MR; Hallett TB; Doherty M; De Luca A; Lundgren JD; Mhangara M; Apollo T; Mellors J; Nichols B; Parikh U; Pillay D; Rinke de Wit T; Sigaloff K; Havlir D; Kuritzkes DR; Pozniak A; van de Vijver D; Vitoria M; Wainberg MA; Raizes E; Bertagnolio S;
    Lancet HIV; 2018 Mar; 5(3):e146-e154. PubMed ID: 29174084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis.
    Gupta RK; Gregson J; Parkin N; Haile-Selassie H; Tanuri A; Andrade Forero L; Kaleebu P; Watera C; Aghokeng A; Mutenda N; Dzangare J; Hone S; Hang ZZ; Garcia J; Garcia Z; Marchorro P; Beteta E; Giron A; Hamers R; Inzaule S; Frenkel LM; Chung MH; de Oliveira T; Pillay D; Naidoo K; Kharsany A; Kugathasan R; Cutino T; Hunt G; Avila Rios S; Doherty M; Jordan MR; Bertagnolio S
    Lancet Infect Dis; 2018 Mar; 18(3):346-355. PubMed ID: 29198909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High levels of pre-treatment HIV drug resistance and treatment failure in Nigerian children.
    Boerma RS; Boender TS; Sigaloff KC; Rinke de Wit TF; van Hensbroek MB; Ndembi N; Adeyemo T; Temiye EO; Osibogun A; Ondoa P; Calis JC; Akanmu AS
    J Int AIDS Soc; 2016; 19(1):21140. PubMed ID: 27836020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drivers of HIV-1 drug resistance to non-nucleoside reverse-transcriptase inhibitors (NNRTIs) in nine southern African countries: a modelling study.
    Riou J; Dupont C; Bertagnolio S; Gupta RK; Kouyos RD; Egger M; L Althaus C
    BMC Infect Dis; 2021 Oct; 21(1):1042. PubMed ID: 34620119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysis.
    Haas AD; Keiser O; Balestre E; Brown S; Bissagnene E; Chimbetete C; Dabis F; Davies MA; Hoffmann CJ; Oyaro P; Parkes-Ratanshi R; Reynolds SJ; Sikazwe I; Wools-Kaloustian K; Zannou DM; Wandeler G; Egger M;
    Lancet HIV; 2015 Jul; 2(7):e271-8. PubMed ID: 26423252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa.
    Boender TS; Kityo CM; Boerma RS; Hamers RL; Ondoa P; Wellington M; Siwale M; Nankya I; Kaudha E; Akanmu AS; Botes ME; Steegen K; Calis JC; Rinke de Wit TF; Sigaloff KC
    J Antimicrob Chemother; 2016 Oct; 71(10):2918-27. PubMed ID: 27342546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pretreatment HIV-drug resistance in Mexico and its impact on the effectiveness of first-line antiretroviral therapy: a nationally representative 2015 WHO survey.
    Ávila-Ríos S; García-Morales C; Matías-Florentino M; Romero-Mora KA; Tapia-Trejo D; Quiroz-Morales VS; Reyes-Gopar H; Ji H; Sandstrom P; Casillas-Rodríguez J; Sierra-Madero J; León-Juárez EA; Valenzuela-Lara M; Magis-Rodríguez C; Uribe-Zuñiga P; Reyes-Terán G;
    Lancet HIV; 2016 Dec; 3(12):e579-e591. PubMed ID: 27658867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bridging the gap between HIV epidemiology and antiretroviral resistance evolution: Modelling the spread of resistance in South Africa.
    Hauser A; Kusejko K; Johnson LF; Wandeler G; Riou J; Goldstein F; Egger M; Kouyos RD
    PLoS Comput Biol; 2019 Jun; 15(6):e1007083. PubMed ID: 31233494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short Communication: High Viral Load and Multidrug Resistance Due to Late Switch to Second-Line Regimens Could Be a Major Obstacle to Reach the 90-90-90 UNAIDS Objectives in Sub-Saharan Africa.
    Guichet E; Aghokeng A; Serrano L; Bado G; Toure-Kane C; Eymard-Duvernay S; Villabona-Arenas CJ; Delaporte E; Ciaffi L; Peeters M
    AIDS Res Hum Retroviruses; 2016 Dec; 32(12):1159-1162. PubMed ID: 27342228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surveillance of HIV-1 pol transmitted drug resistance in acutely and recently infected antiretroviral drug-naïve persons in rural western Kenya.
    Onywera H; Maman D; Inzaule S; Auma E; Were K; Fredrick H; Owiti P; Opollo V; Etard JF; Mukui I; Kim AA; Zeh C
    PLoS One; 2017; 12(2):e0171124. PubMed ID: 28178281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human resources for treating HIV/AIDS: needs, capacities, and gaps.
    Bärnighausen T; Bloom DE; Humair S
    AIDS Patient Care STDS; 2007 Nov; 21(11):799-812. PubMed ID: 17944556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contemporary issues on the epidemiology and antiretroviral adherence of HIV-infected adolescents in sub-Saharan Africa: a narrative review.
    Adejumo OA; Malee KM; Ryscavage P; Hunter SJ; Taiwo BO
    J Int AIDS Soc; 2015; 18(1):20049. PubMed ID: 26385853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addressing Pediatric HIV Pretreatment Drug Resistance and Virologic Failure in Sub-Saharan Africa: A Cost-Effectiveness Analysis of Diagnostic-Based Strategies in Children ≥3 Years Old.
    Siriruchatanon M; Liu S; Carlucci JG; Enns EA; Duarte HA
    Diagnostics (Basel); 2021 Mar; 11(3):. PubMed ID: 33801154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protease Inhibitor Resistance in the First 3 Years of Second-Line Antiretroviral Therapy for HIV-1 in Sub-Saharan Africa.
    Boender TS; Hamers RL; Ondoa P; Wellington M; Chimbetete C; Siwale M; Labib Maksimos EE; Balinda SN; Kityo CM; Adeyemo TA; Akanmu AS; Mandaliya K; Botes ME; Stevens W; Rinke de Wit TF; Sigaloff KC
    J Infect Dis; 2016 Sep; 214(6):873-83. PubMed ID: 27402780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance at virological failure using boosted protease inhibitors versus nonnucleoside reverse transcriptase inhibitors as first-line antiretroviral therapy--implications for sustained efficacy of ART in resource-limited settings.
    Hill A; McBride A; Sawyer AW; Clumeck N; Gupta RK
    J Infect Dis; 2013 Jun; 207 Suppl 2():S78-84. PubMed ID: 23687293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging HIV-1 drug resistance after roll-out of antiretroviral therapy in sub-Saharan Africa.
    Hamers RL; Sigaloff KC; Kityo C; Mugyenyi P; de Wit TF
    Curr Opin HIV AIDS; 2013 Jan; 8(1):19-26. PubMed ID: 23143140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Scale-up of antiretroviral treatment in sub-Saharan Africa is accompanied by increasing HIV-1 drug resistance mutations in drug-naive patients.
    Aghokeng AF; Kouanfack C; Laurent C; Ebong E; Atem-Tambe A; Butel C; Montavon C; Mpoudi-Ngole E; Delaporte E; Peeters M
    AIDS; 2011 Nov; 25(17):2183-8. PubMed ID: 21860346
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.